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The numerous reports (1) showing that suppressor T  cells are generated in response 
to growth of immunogenic tumors serve to provide an explanation for the paradoxical 
growth of these tumors in their immunocompetent syngeneic hosts. A  recent publi- 
cation  (2)  from this  laboratory revealed,  for example,  that  progressive growth of a 
transplantable murine tumor, the Meth A  fibrosarcoma, results in the generation in 
the host of a T  cell-mediated state of immunosuppression that prevents the regression 
of this tumor by passively transferred, tumor-sensitized T  cells from immune donors. 
The presence of suppressor T  cells  in  the  tumor-bearing host was  revealed  in  two 
ways:  first,  by  showing  that  in  order  to  demonstrate  adoptive  T  cell-mediated 
regression of established tumors, it was necessary to use tumor-bearing recipients that 
had been made T  cell deficient by thymectomy and gamma irradiation;  second, by 
demonstrating that  adoptive T  cell-mediated  regression of tumors  in  these  T  cell- 
deficient recipients could be inhibited by prior infusion of splenic T  cells from T  cell- 
intact, tumor-bearing donors. It was concluded that the failure of  passively transferred, 
sensitized T  cells  to cause tumor regression in T  cell-intact mice was caused by the 
presence in these mice of a  tumor-induced state of T  cell-mediated immunosuppres- 
sion. 
The main purpose of this paper is to show that a  strikingly similar mechanism of 
immunosuppression is generated in response to growth of the P815 mastocytoma. It 
will  show,  in  addition,  that  passive  transfer  of sensitized  T  cells  not  only causes 
complete regression of the primary tumor but  also causes the destruction of tumor 
metastases. 
Materials and Methods 
Mice.  B6D2  (C57BL/6  ×  DBA/2),  F1,  CB6  (BALB/c  ×  C57BL/6)F1,  DBA/2,  and 
BALB/c mice of either sex were used when they were between 8 and 12 wk of age. They were 
supplied  by the Trudeau Institute Animal Breeding Facility. 
Tumors.  The P815 mastocytoma syngeneic in DBA/2 mice was originally  obtained from 
Dr. Virginia  Evans of the National Cancer Institute,  Tissue Culture Section, Bethesda,  Md. 
The Meth A fibrosarcoma  syngeneic in BALB/c mice was obtained from Dr. Lloyd J. Old of 
the Memorial  Sloan-Kettering  Cancer Center,  New York. The tumors were subcuitured  for 
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several weeks in Fisher's medium (Grand Island Biological Co., Grand Island, N. Y.) containing 
15% fetal calf serum (FCS) x before being passaged several times as ascites  in the peritoneal 
cavities of syngeneic mice. The tumor cells thus grown were washed and resuspended in Fisher's 
medium containing 20% FCS and 10% dimethyl sulfoxide, dispensed into a large number of 
small vials, and cryopreserved over liquid nitrogen. Before each experiment, a vial was thawed 
and the cells washed in phosphate-buffered saline (PBS)  and grown as an ascites  in semisyn- 
geneic mice. The ascites tumor cells were harvested 6-8 d after implantation in PBS containing 
10 U heparin/ml. After two washes in PBS, they were resuspended to the desired concentration 
in PBS for implantation in experimental, semisyngeneic  recipients. The standard procedure for 
experimental animals was to inject 106 tumor cells in the right hind footpad, and to follow 
tumor growth by measuring changes against time in the thickness of the footpad with dial 
calipers. 
Tumor Excision.  Tumors to be excised  were initiated by implanting 106 P815 tumor cells 
intradermally in the belly region. At progressive stages of tumor growth, mice were selected for 
tumor excision and anesthetized with Nembutol. Intradermal tumors were carefully excised 
along with  a  generous portion of surrounding normal tissue,  and the  incision closed  with 
stainless steel surgical clips. After tumor excision, mice were examined periodically for evidence 
of tumor metastases and regrowth of their primary tumor. Mice showing evidence of tumor 
regrowth at the excision site were excluded from the study so that survival curves only reflected 
death from metastatic disease. 
Tumor-immune Donor Mice.  Mice were immunized by injecting them intradermally in the 
belly region, or in a hind footpad with 2 ×  106 tumor cells admixed with 100/~g of Formalin- 
killed Corynebacterium parvum (Burroughs Wellcome Co., Research Triangle Park,  N.  C.)  in a 
volume of 0.05  ml of PBS.  This results in an initial 9-d period of tumor growth followed  by 
complete tumor regression within 2 wk. During this time, strong specific immunity to growth 
of a  tumor implant develops (E. S. Dye and R. J.  North, unpublished observations). Spleen 
cells were harvested from these mice soon after complete tumor regression,  diced into small 
pieces,  and gently pushed through a  200-mesh stainless steel  screen into PBS containing 1% 
FCS. The cells were triturated with a Pasteur pipette to break up clumps, and passed through 
six  layers of sterile surgical gauze. They were then washed  in PBS  and resuspended to an 
appropriate concentration in PBS for intravenous injection via a lateral tail vein. 
Donors of Suppressor Cells.  Suppressor cell  donors were  mice carrying  15-d  progressively 
growing tumors initiated by a hind footpad injection of 2 ×  106 tumor cells. The spleen cells of 
these donors were prepared in the same way as immune spleen cells. 
T  Cell-deficient Test Recipients.  Mice were made T  cell-deficient (TXB) at 4 wk of age by 
thymectomy followed  7 d  later by 900 rad of whole body gamma irradiation delivered by a 
lS7Ce irradiator at a dose rate of 29.5 rad/min. The mice were infused intravenously with  10  7 
syngeneic bone marrow cells within 2 h of irradiation and employed in experiments after an 
additional 6 wk. 
Treatment with Anti-Thy-l.2 Antibody.  Lyophilized anti-Thy-l.2 FTD5 monoclonal IgM an- 
tibody (Sera Lab, Accurate Chemical & Scientific Corp., Westbury, N. Y.) was dissolved in a 
volume of distilled water equal to the original volume of ascites. It was divided and stored at 
-70°C  and  thawed  as  needed.  When  tested  against  mouse  thymocytes,  the  apportioned 
antibody solution had a cytotoxic titer of>l in 50,000. Spleen cells were treated at 5 ×  107/ml 
in a  1:1,000 dilution of the antibody for 45 min on ice. The cells were  then centrifuged and 
incubated for 30 min at 37°C in the same volume of a  1:15 dilution of rabbit serum (Low-Tox- 
M rabbit complement; Accurate Chemical & Scientific Corp.) as a source of complement. After 
washing twice in PBS-FCS, the cells were resuspended to the desired concentration in PBS for 
intravenous infusion. 
Results 
Demonstration  of Adoptive  T  Cell-mediated  Tumor  Regression  Requires  T  Cell-deficient 
Recipients.  In the first series of experiments, the P815 mastocytoma and the Meth A 
1  Abbreviations used in this paper: FCS, fetal calf serum; PBS, phosphate-buffered saline; TXB, thymeeto- 
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fibrosarcoma growing in normal mice or in T  cell-deficient mice, were compared in 
terms of their susceptibility to intravenously infused spleen cells from appropriately 
immunized donors. The results in Fig.  1 show that the two tumors behaved in the 
same way. In both cases, intravenous infusion of immune spleen cells resulted after 
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FIG.  1.  Evidence that intravenous infusion of 1.5 ×  10  s spleen cells from immune donor mice on 
day 4  of tumor  growth  results,  after a  delay,  in  complete  tumor  regression  in  T  cell-deficient 
recipients (TXB), but not in normal recipients. Means of five mice per time point. 
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Fxo.  2.  Evidence  that donor spleen cells that  mediate regression of the P815 mastocytoma in T 
cell-deficient recipients are T cells. Treatment  of spleen cells with monoclonal anti-Thy-l.2 plus 
complement ablated their capacity to cause tumor regression. Means of five mice per time point. 1036  T  CELL  SUPPRESSION  OF  ADOPTIVE  IMMUNOTHERAPY 
in  recipients  that  had  been  made  T  cell  deficient  by  thymectomy  and  gamma 
irradiation. 
Evidence  that  regression of the  P815  mastocytoma was mediated  by T  cells was 
obtained by determining whether immune spleen cells from mastocytoma-immunized 
donors failed to cause tumor regression if they were first incubated with anti-Thy-1.2 
antibodies and complement. The results in Fig.  2 show that anti-Thy-l.2 treatment 
completely ablated the capacity of these spleen cells to regress tumors growing in T 
cell-deficient recipients.  Therefore,  there can  be little  doubt  so far as this model is 
concerned that the cells that mediate regression of the P815 mastocytoma, like those 
that mediate regression of the Meth A fibrosarcoma (2), are Thy-l-positive T  cells. 
Passively Transferred, Sensitized T  Cells Destroy Tumor Metastases.  Unlike the Meth A 
fibrosarcorna, which does not metastasize, the P815 mastocytorna metastasizes to the 
draining lymph nodes, spleen, and eventually the lungs. As a  result, the P815 tumor 
kills its host much sooner than the Meth A  tumor. In addition,  it was observed that 
T  cell-deficient mice injected intradermally, or in a hind footpad with  106 P815 cells 
developed metastases and  died  2-3 wk earlier than  normal mice implanted with  a 
similar number of tumor cells.  Based on this observation,  it seemed likely that  the 
passive transfer of immune cells into tumor-bearing, T  cell-deficient mice described 
in  the  previous section,  not  only caused  regression of the  primary tumor,  but  also 
eliminated  already  seeded  metastases.  Evidence  to  support  this  interpretation  is 
illustrated in Fig. 3, which shows the results of an experiment designed to measure the 
survival  time  of T  cell-deficient  mice  and  normal  mice  that  had  their  primary 
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F[~.  3.  Evidence that intradermal growth of the P815 tumor causes lethal tumor metastases to be 
seeded much sooner in T  cell-deficient (TXB) mice than in normal mice. Tumors growing in normal 
and  TXB  mice were  excised either 3  or  6  d  after  implantation, and  the  mice were  examined 
periodically  for tumor metastases and survival. The survival curves show that 80% of the TXB mice 
were seeded with metastases by day 3 of tumor growth and  100% by day 6.  Mice with metastases 
had a  median survival time of  19 d.  In contrast, T  cell-competent mice remained free of tumor 
metastases for the 60-d period of observation. Percent survivors is based on  10 mice per group. EARL S.  DYE  AND ROBERT J.  NORTH  1037 
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Fie.  4.  Evidence that immune cells can inhibit the growth of already seeded tumor metastases in 
a T cell-deficient host. Intradermal P815 tumors, growing in T cell-deficient mice, were excised on 
day 6 of tumor ~rowth, and 4 h later the mice were infused with either 1.5 ×  10  a immune spleen 
cells or 1.5 X 10  normal spleen cells. The survival curves show that whereas immune spleen cells 
protected mice from tumor metastases for the 60-d period of  observation, recipients of normal spleen 
cells all died of tumor metastases with a median survival time of 19 d. Percent survivors is based on 
10 mice per group. 
survival curves that 80% of the T  cell-deficient mice were seeded with metastases by 
day 3 of tumor growth and  100% by day 6. In contrast, control mice all survived the 
60-d period of observation and showed no signs of developing metastases. 
Because  the T  cell-deficient mice  develop  metastatic disease before the  6th  d  of 
primary tumor growth  (Fig. 3), and because the passive transfer of tumor-sensitized 
T  cells on day 4  of tumor growth does not cause the regression of tumors in T  cell- 
deficient recipients for a  further 6  d  (Fig.  1),  it follows that  the passively transferred 
T  cells must  have  caused  the  destruction  of already established metastases.  Direct 
evidence to support this interpretation can be seen in Fig. 4, which shows the results 
of an experiment that tested the capacity of 1.5 ×  108 tumor-immune spleen cells, or 
1.5  ×  10  s  normal  spleen  cells,  to  protect  T  cell-deficient recipients  that  had  their 
primary tumors excised on day 6 of tumor growth. It can be seen that an infusion of 
immune  spleen  cells  4  h  after  tumor  excision  protected  these  mice  from  tumor 
metastases  for  the  60-d  period of observation,  whereas  recipients of normal  spleen 
cells died rapidly with a  median survival time of 19 d. There is no doubt, therefore, 
that the survival of adoptively immunized, tumor-bearing, T  cell-deficient recipients 
depended on the capacity of intravenously infused, sensitized T  cells to seek out and 
destroy metastases as well as the primary tumor. 
Inhibition of Adoptive T Cell-mediated Tumor Regression by Spleen Cells  from Tumor-bearing 
Donors.  It was anticipated on  the basis of the foregoing results, and  those obtained 
previously with the Meth A fibrosarcoma (2), that adoptive T  cell-mediated regression 
of the  P815  mastocytoma  in  T  cell-deficient recipients would  be  inhibited  by  an 
appropriately timed infusion of spleen cells from T  cell-intact, tumor-bearing donors. 
That this was the case can be seen in Fig. 5, which shows the results of an experiment 
that  measured  the  effect  of an  intravenous  infusion  of  1.5  ×  108  spleen cells from 
15-d tumor-bearing donors on regression caused by the same number of spleen cells 
from  immune  donors.  It  can  be seen  that  an  infusion of spleen cells from  immune 
donors  completely inhibited  the ability of the  immune  spleen cells to  cause  tumor 
regression in T  cell-deficient test recipients. Normal spleen cells, in contrast, had no 
inhibitory effect. 
Evidence that the spleen cells from tumor-bearing donors that inhibit the expression 1038  T  CELL SUPPRESSION OF ADOPTIVE IMMUNOTHERAPY 
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FIG. 5.  Evidence that adoptive T  cell-mediated  regression of the P815 mastocytoma  in T  cell- 
deficient recipients can be inhibited by intravenous  infusion of spleen cells from tumor-bearing 
donors. On day 4 of tumor growth, the recipients received 1.5 x  lO  s spleen cells from 15-d tumor- 
bearing donors, or normal donors 1 h before receiving 1.5 X 10  s spleen cells from immune donors. 
Means of five mice per time point. 
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Fla. 6.  Treatment of spleen ceils from 15-d tumor-bearing donors with anti-Thy-l.2 plus comple- 
ment essentially eliminated the capacity of these cells to inhibit immune spleen cells from regressing 
the P815 mastocytoma in T cell-deficient recipients. Means of five mice per time point. 
of adoptive immunotherapy are T  cells is supplied in Fig. 6, where it can be seen that 
their suppressor activity was almost totally eliminated by incubating them with anti- 
Thy-l.2 antibodies and complement. 
It will be  noted  that  suppression  was  not  as strong  in  this experiment  as in  the 
experiment shown in Fig. 5. That this was probably a  result of the presence of fewer 
suppressor cells in the spleens of these suppressor donors is shown in Fig. 8 below. 
Effect  of Timing  of Suppressor Cell Infusion on  Adoptive Immunity.  A  characteristic 
feature  of adoptive T  cell-mediated regression  of the  P815  mastocytoma,  and  the 
Meth A  fibrosarcoma (2), is that there is a  relatively long delay (6-7 d) between the 
time that  immune cells are infused intravenously and the time the tumors begin to 
regress. One possible reason for this delay might be that the infused immune T  cell 
population  needs  to  replicate  in  order  to  reach  a  large  enough  number  to  cause 
regression. According to this interpretation, the stimulus for T  cell replication would 
be  supplied  by  antigens  of  the  recipient's  growing  tumor,  and  the  function  of 
suppressor T  cells would be to prevent this replication. If so, then one would expect 
suppressor T  cells to be more effective if they were  infused before immune  T  cells EARL  S.  DYE  AND  ROBERT  J.  NORTH  1039 
have had time to expand in number. This possibility was investigated by measuring 
the degree to which adoptive T  cell-mediated tumor regression was inhibited when 
1.5  ×  108 suppressor spleen cells were  infused 2  d  before, at the time of, or 4  d  after 
the  infusion  of  1.5  ×  108  immune  cells.  It  was  found  (Fig.  7)  that  when  suppressor 
cells were  infused either at  the time of, or "2 d  before immune  cells,  tumor  regression 
was completely  suppressed.  In contrast, when  suppressor cells were  infused 4  d  after 
immune  cells, the onset of suppression was greatly delayed in that  tumor  growth  was 
halted  for 8  d  before suppressor function emerged.  It can be predicted  on the basis of 
these results that suppressor T  cells will exert little or no influence if they are infused 
after  tumor  regression  has  already  commenced.  This  possibility  is  currently  being 
tested. 
Effect of Varying the Ratio of Immune T  Cells to Suppressor T  Cells on  Tumor Regression. 
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Fro.  7.  Effect on tumor regression in T  cell-deficient recipients of varying the time of infusing 
suppressor spleen cells relative to the time of infusing immune spleen cells.  Immune spleen cells 
were infused on day 4 of tumor growth, and suppressor cells were infused 2 d before, at the time of, 
or 4 d later. Delaying the infusion of suppressor cells by 4 d resulted in a greatly reduced suppressor 
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FIG. 8.  Effect of varying the ratio of immune spleen cells  to suppressor s  psleen cells  infused on 
tumor regression in T  cell-deficient recipients. A ratio of 1:1 equals 1.5 ×  10  immune spleen cells 
to 1.5 ×  l0  s suppressor spleen cells given 1 h apart on day 4 of tumor growth. It is obvious from the 
graphs on the right that the larger the number of immune cells  infused, the sooner the onset of 
regression.  It can be seen in the graphs on the left that the larger the proportion of suppressor cells, 
the greater was the level of suppression expressed. 1040  T  CELL SUPPRESSION OF  ADOPTIVE IMMUNOTHERAPY 
The experiments up to this point were based on the use of one organ equivalent (~ 1.5 
×  10  s)  of donor spleen cells to passively transfer immunity and suppression.  It was 
important  for the design of future experiments, however, to determine the effect of 
varying the ratio of immune T  cells to suppressor T  cells infused.  The results of an 
experiment that measured the effect on tumor regression of infusing different ratios of 
immune to suppressor cells into T cell-deficient recipients bearing 4-d tumors is shown 
in Fig. 8.  It can be seen in the right panel that decreasing the number of suppressor 
cells relative to the number of immune cells resulted  in  increasing periods of delay 
before suppressor function  was expressed.  In the case of the smallest proportion of 
suppressor cells infused, enough time elapsed to enable effector T  cells to cause almost 
complete  tumor  regression.  Therefore,  in  all  cases,  suppressor  function  eventually 
emerged and  the  tumors regrew at  a  rapid  rate. The  left panel of Fig.  8  serves to 
show, in the absence of suppressors, that the larger the number of immune spleen cells 
infused, the earlier the onset of tumor regression. 
Discussion 
This  paper shows  that  growth  of the  P815  mastocytoma in  semisyngeneic mice 
evokes the generation of a state of T  cell-mediated immunosuppression. This conclu- 
sion  is  based  on  two  major  findings:  first,  that  it  is  possible  to  regress  the  P815 
mastocytoma by passive transfer of tumor-sensitized T  cells, but only if the tumors 
are growing in recipient mice that have been made T  cell-deficient by thymectomy 
and  gamma  irradiation;  second,  that  adoptive  T  cell-mediated  regression  of this 
tumor in T  cell-deficient recipients can be inhibited by an infusion of splenic T  cells 
from T  cell-intact tumor-bearing donors. It follows, therefore, that failure of passively 
transferred, sensitized T  cells to regress tumors in T  cell-intact mice is caused by the 
presence in these mice of a  tumor-induced mechanism of T  cell-mediated immuno- 
suppression. The results as a whole are strikingly similar, therefore, to those obtained 
previously (2) with the Meth A fibrosarcoma, and make it highly likely that the same 
mechanism of immunosuppression will be found to be generated in response to the 
growth of many other immunogenic tumors. 
The results with the P815 mastocytoma, however, are immunotherapeutically more 
interesting,  because this tumor metastasizes to cause systemic disease.  Moreover,  it 
does so much more rapidly in the T  cell-deficient test recipients used in this study. It 
was shown, by excising primary tumors at progressive time intervals, that metastases 
are seeded before day 6 of primary tumor growth in T  cell-deficient mice, but not in 
normal mice. Considering the knowledge that intravenous  infusion of immune cells 
on day 4 of tumor growth does not cause tumor regression in T ceU-deficient recipients 
until  6 d  later, it follows that survival of these recipients not only depended  on the 
capacity of the infused T  cells to destroy the primary tumor, but also on the capacity 
of these cells to seek out and destroy established metastases. It was demonstrated, in 
support  of this  interpretation,  that  all T  cell-deficient  mice that  received  immune 
spleen cells 4 h after removal of their day 6 primary tumors survived a 60-d period of 
observation and remained free of palpable tumor metastases. In contrast, the recipients 
of normal §pleen cells all died of tumor metastases with a median survival time of 19 
d. So far as the P815 mastocytoma is concerned, it seems obvious that tumor cells that 
give  rise  to  metastases  are  not  selected  on  the  basis  of  their  capacity  to  avoid 
destruction by T  cell-mediated immunity. EARL S. DYE AND ROBERT J.  NORTH  1041 
It was argued in a previous publication (2) that the generation of suppressor T cells 
would  seem  the  most  plausible  explanation  for  why  immunogenic  tumors  grow 
progressively in their immunocompetent hosts, in spite of the generation of an initial 
state  of concomitant  anti-tumor  immunity.  There  is  in  vitro evidence  (3)  in  this 
connection,  that  cytolytic T  cells  are  generated  in  syngeneic mice  in  response  to 
growth of the P815 mastocytoma, but that the response is of low magnitude and short 
duration. Indeed, it was shown in this same study (3) that the loss of cytolytic T  cells 
is associated with the acquisition by the host of T  cells that can suppress a secondary 
cytolytic response  to  the  P815  mastocytoma  in  vitro.  Similar  evidence has  been 
obtained in  this laboratory ((2. D.  Mills,  R. J.  North, and  E.  S.  Dye, unpublished 
observations). There seems little doubt, therefore, that tumor-induced T cell-mediated 
immunosuppression is generated in response to growth of the P815 mastocytoma, and 
that  this will  prove to be the major obstacle to attempts  to regress this  tumor by 
immunotherapy.  The specificity of suppression  is  currently under study using  the 
Meth A fibrosarcoma and the P815 mastocytoma in semisyngeneic D2CF1 mice. 
So far as adoptive immunotherapy is concerned, it is apparent from a review of the 
literature (4), that although there is relatively little difficulty in adoptively immuniz- 
ing against  the growth of tumor implants, great difficulty is experienced in demon- 
strating adoptive T  cell-mediated immunity against  established  tumors.  In  fact, to 
cause even partial regression of established tumors requires the infusion of very large 
numbers of sensitized cells. However, an exception to this general finding recently has 
been described for a  syngeneic, virus-induced rat tumor, where successful immuno- 
therapy of large tumors was  achieved by intravenous infusion of sensitized T  cells 
generated in vitro (5).  We have repeatedly failed to regress the P815 mastocytoma 
and  Meth  A  fibrosarcoma in  T  cell-intact mice, even by repeatedly infusing very 
large numbers of immune spleen cells. This indicates that, in the case of these tumors, 
the state of T  cell-mediated immunosuppression is relatively strong. 
A significant finding revealed by this study is that although immune T  cells can be 
functionally dominant  in the presence of relatively small numbers of suppressor T 
cells, suppression eventually dominates. It was shown, for example, that whereas one 
spleen equivalent of suppressor cells can completely prevent one spleen equivalent of 
immune cells from regressing tumors in T  cell-deficient test recipients, reducing the 
number  of suppressor  cells  infused  to  a  quarter  spleen  equivalent  allows  infused 
immune cells to cause almost complete tumor regression. However, suppressor function 
eventually emerged,  and  the  tumors  regrew  at  a  rapid  rate.  A  similar  result  was 
obtained by delaying the  time that  suppressor cells were infused.  Taken  together, 
these results indicate the possibility that the function of suppressor cells in this model 
is to inhibit the replication of passively transferred immune T  cells, and thereby to 
prevent these cells from reaching a  large enough number to cause tumor regression. 
Thus, delaying the time of infusion of suppressor cells or infusing a smaller number 
allows enough time for the infused immune cells to expand in number in response to 
antigens supplied by the reclpient's growing tumor. The reason suppressor function 
eventually emerges and becomes dominant might be that suppressor T  cells also are 
stimulated to replicate in response to antigens supplied by the growing tumor. This 
hypothesis is currently being tested. 
Even so, it remains to be explained why the spleens of immune donors themselves 
and of normal donors do not contain suppressor precursors that can be stimulated to 1042  T  CELL SUPPRESSION OF  ADOPTIVE IMMUNOTHERAPY 
replicate and differentiate in response to tumor antigens  in the T  cell-deficient test 
recipient. One possibility might be that even though suppressor precursors are present 
in  immune  and  normal  spleens,  they  are  present  in  such  small  numbers  that  the 
tumors have enough time to be completely regressed by infused immune T  cells before 
suppressor T  cells replicate  to  dominant  numbers.  Alternatively,  the  precursors  of 
suppressor  T  cells  may  be  relatively  short-lived  and  may  be  newly  formed  cells 
released by the thymus, as appears to be the case for the Lyt-123 subpopulation of 
suppressor T  cells that cooperate with other T  cells in other models of T  cell-mediated 
suppression  (6,  7). These precursors would not be available in the thymeetomized T 
cell-deficient test recipients used in this study. 
Summary 
Progressive  growth  of the  P815  mastoeytoma in  semisyngeneic  mice  evokes the 
generation of a  T  cell-mediated mechanism of immunosuppression that inhibits the 
capacity of passively transferred, tumor-sensitized T  cells from regressing this tumor 
in recipient mice. This conclusion is based on two findings:  (a)  that it is possible to 
demonstrate adoptive T  cell-mediated regression of established  tumors, but  only if 
the tumors are growing in T  cell-deficient  recipients,  and  (b)  that  adoptive T  cell- 
mediated regression of tumors in these recipients can be inhibited by the infusion of 
splenic  T  cells  from T  cell-intact,  tumor-bearing donors.  The results  of additional 
experiments designed to measure the effect of decreasing the number of suppressor 
cells and the time that they are infused,  relative to immune cells, indicate that the 
function  of suppressor  cells  in  this  model  is  to  inhibit  the  replication  of passively 
transferred  immune T  cells.  The  results  obtained  with  the  P815  mastocytoma are 
similar to those obtained previously with a  chemically induced  fibrosarcoma. They 
show, in addition,  that passively transferred immune cells are capable of destroying 
already seeded metastases in T  cell-deficient recipients. 
Received  for publication 19 May 1981. 
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